Reporting owner · CIK 0001843601

Patel Sandip I

SEC Form 4 history for the last 180 days across 2 companies, 11 transactions and 3 filings.

DIRAkari Therapeutics Plc
Open-market transaction mix100% buys2 buys · 0 sales

Period: Last 180 days

Trade dates in this period: Aug 18, 2026 – Oct 14, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings3Form 4 records
Buying$20.7k2 purchases
Selling$00 sales
Net value+$20.7kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Patel Sandip I transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
AKTXAkari Therapeutics Plc
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
−$100kView disclosure →
AKTXAkari Therapeutics Plc
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
−$62.5kView disclosure →
AKTXAkari Therapeutics Plc
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Derivative securitySEC filing ↗
$0View disclosure →
AKTXAkari Therapeutics Plc
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Derivative securitySEC filing ↗
$0View disclosure →
AKTXAkari Therapeutics Plc
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$2View disclosure →
AKTXAkari Therapeutics Plc
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$2View disclosure →
AKTXAkari Therapeutics Plc
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
SEC filing ↗
$34.1kView disclosure →
AKTXAkari Therapeutics Plc
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
SEC filing ↗
$95.6kView disclosure →
ATCHAtlasClear Holdings, Inc.
Chief Financial Officer · General Counsel
CFO, GC
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Derivative securitySEC filing ↗
$0View disclosure →
ATCHAtlasClear Holdings, Inc.
Chief Financial Officer · General Counsel
CFO, GC
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
$9.88kView disclosure →
ATCHAtlasClear Holdings, Inc.
Chief Financial Officer · General Counsel
CFO, GC
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Amended
Form 4/A: an amendment to a filing.
SEC filing ↗
$10.9kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at AtlasClear Holdings, Inc. on Sep 25, 2026 valued at $9,875.

Review SEC filing
Latest sale

No open-market insider sale is available.

Monthly open-market activity

Last 3 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 202600$0$0$0
Sep 202620$20,740$0+$20,740
Oct 202600$0$0$0

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$10.4k
Median P/S size$10.4k
Direct11
Indirect0
Oct 14, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

4 observations · Aug 18, 2026 – Oct 14, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 14, 202638,877 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 18, 202624,512Oct 16, 2026View transaction
Oct 5, 202628,825Oct 16, 2026View transaction
Oct 14, 202632,691Oct 16, 2026View transaction
Oct 14, 202638,877Oct 16, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Patel Sandip I Insider Activity FAQ

SEC Form 4 context

Who is Patel Sandip I?

Patel Sandip I is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001843601.

Which companies has Patel Sandip I reported transactions for?

Akari Therapeutics Plc, AtlasClear Holdings, Inc.

When was Patel Sandip I's latest insider buy?

The insider reported a buy at AtlasClear Holdings, Inc. on Sep 25, 2026 valued at $9,875.

When was Patel Sandip I's latest insider sale?

No open-market insider sale is recorded in the last 180 days. Earlier filings are outside the visible history.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.